Document is current
Any future updates will be listed below
-
Authors
Hart, Xenia M.
Hiemke, Christoph
Eichentopf, Luzie
Lense, Xenija M.
Clement, Hans Willi
Conca, Andreas
Faltraco, Frank
Florio, Vincenzo
Grüner, Jessica
Havemann-Reinecke, Ursula
Molden, Espen
Paulzen, Michael
Schoretsanitis, Georgios
Riemer, Thomas G.
Gründer, Gerhard
-
Funding
Funding for this research was provided by:
Zentralinstitut für Seelische Gesundheit (ZI)
- License Information
-
More Information
Article History
Received: 20 April 2022
Accepted: 1 September 2022
First Online: 5 October 2022
Declarations
:
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. GG has served as a consultant for Allergan, Boehringer Ingelheim, Institute for Quality and Efficiency in Health Care (IQWiG), Janssen-Cilag, Lundbeck, Otsuka, Recordati, Roche, ROVI, Sage, and Takeda. He has served on the speakers’ bureau of Gedeon Richter, Janssen Cilag, Lundbeck, Otsuka, and Recordati. He has received grant support from Boehringer Ingelheim, Lundbeck, and Saladax. He is co-founder and/or shareholder of Mind and Brain Institute GmbH, Brainfoods GmbH, OVID Health Systems GmbH and MIND Foundation gGmbH. CH has served on the speakers’ bureau of Otsuka. GS has served as a consultant and has received speaker fees from HLS Therapeutics. MP has received speaker’s fees from Janssen, ROVI, Neuraxpharm, Lundbeck, and Otsuka. He has served as a consultant for Novartis, Otsuka, and ROVI. MP is an editor of an internet-based drug–drug interaction program ().
